How Media Outlets Are Reacting to Trump’s Psychedelics Executive Order
Trump’s executive order on psychedelics pushed a once fringe issue into the center of health policy. The coverage shows a clear pattern.
Read More
FDA Grants Priority Vouchers to Three Psychedelic Drug Programs
The FDA's decision could deliver the first psychedelic medicine approved by the FDA as soon as this summer.
Read More
Why the Trump Psychedelics Executive Order Makes This the Most Important Moment to Join the Healing Health Alliance
Something happened in Washington last week that changes the economics of running a ketamine or psychedelic-adjacent clinic in America. President Trump’s April 18, 2026 executive order — Accelerating Medical Treatments for Serious Mental Illness — formally directed the FDA to expedite review of psychedelic therapies, instructed the DEA to remove administrative barriers to research and […]
Read More
What Trump’s Psychedelics Executive Order Means for Ketamine Practitioners
Here's why ketamine clinics are the infrastructure that defines the next era of psychedelic medicine — and what operators should do now.
Read More
What Trump’s Psychedelics Executive Order Means for Psilocybin
The executive order mentions ibogaine, but psilocybin may be the real winner. How priority vouchers, Right to Try, and rescheduling reshape the path to FDA approval.
Read More
Is Ibogaine Safe? Cardiac Risks, the Magnesium Protocol, and What the Stanford Data Shows
Ibogaine's cardiac risk is real. The Stanford MISTIC protocol has reshaped the picture. A complete 2026 guide to screening, monitoring, and clinic red flags.
Read More
Right to Try Ibogaine: What the New Federal Pathway Actually Offers — and What It Doesn’t
The new federal Right to Try pathway for ibogaine explained: who qualifies, what has to happen first, and why it won't be a prescription in 2026.
Read More
What Trump’s Psychedelics Executive Order Actually Means for Ibogaine
It is the most significant federal action on psychedelic medicine ever taken by a U.S. president. And Ibogaine is named twice in the text.
Read More
Trump Signs Executive Order to Accelerate FDA Review of Psychedelic Therapies
Trump framed the order as a response to the mental health crisis facing American veterans. Psychedelic therapy advocates are watching the move closely.
Read More
Magic Mushrooms Move Mainstream as Science and Policy Lag Behind
Psilocybin is moving into the mainstream faster than science and policy can keep up. Will this interest in move the regulatory needle?
Read More